Sex-specific differences in the prevalence of intermediate hyperglycaemia states: a systematic review and meta-analysis
Cooper L, Porter I, Meek C, et al.
Diabet Med. Pub. online 10 Mar 2026.
Leggi
Weight loss as a determinant of histological improvement in metabolic dysfunction-associated steatotic liver disease in people with obesity. A systematic review and network meta-analysis of randomised clinical trials
Monami M, Belluzzi A, Buscemi S, et al.
Diabetes Obes Metab. Pub. online 9 Mar 2026.
Leggi
Metabolic liver disease: a summary of major guidelines and identifying opportunities to improve future guidelines
Bril F
Diabetes Obes Metab. Pub. online 13 Mar 2026.
Leggi
Efficacy and safety of cagrilintide and cagrisema versus semaglutide as anti‐obesity medications: a systematic review, meta‐analysis and meta‐regression
Ahmed M, Hassan M, Tahir M, et al.
Diabetes Obes Metab. Pub. online 16 Mar 2026.
Leggi
Diabetes management in people undergoing metabolic-bariatric surgery: a guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group
Stephens JW, Dhatariya K, Beamish AJ, et al.
Diabet Med. Pub. online 16 Mar 2026.
Leggi
A call to action: a consensus statement on knowledge gaps and research priorities on the management of women with early onset type 2 diabetes in the preconception, pregnancy and postnatal periods: A report from the Diabetic Medicine Symposium at the Diabetes UK Annual Professional Conference, 2025
White SL, Schoenaker D, Mackin S, et al.
Diabet Med. Pub. online 13 Mar 2026.
Leggi
III EDIZIONE STATI GENERALI SUL DIABETE FeSDI
Carissimi Soci, siamo giunti alla III edizione degli Stati Generali sul Diabete, promossa da FeSDI in collaborazione con l’Intergruppo Parlamentare “Obesità, diabete e malattie croniche non trasmissibili”. L’evento si è svolto a Roma il 19 marzo, anche quest’anno presso la prestigiosa sede del CNEL – Consiglio Nazionale dell’Economia e del Lavoro. L’edizione 2026 ha avuto l’obiettivo di far emergere proposte…
Leggi
Identifying predictors of early treatment intensification in individuals with type 2 diabetes treated with GLP-1 receptor agonists: a machine learning-based analysis of a large real world cohort
Falcetta P, Zilich R, Baccetti F, et al.
Diabetes Obes Metab. Pub. online 9 Mar 2026.
Leggi
Cardiovascular outcomes of GLP-1RA vs SGLT2i in MASLD and type 2 diabetes: real-world evidence
Yang CC, Wu JY, Cheng YY, et al.
Diabetes Res Clin Pract. Pub. online 7 Mar 2026.
Leggi